Beam Therapeutics Inc.

Developing precision genetic medicines using base editing to provide cures for serious diseases.

BEAM | US

Overview

Corporate Details

ISIN(s):: US07373V1052
LEI:
Country:: United States of America
Address:: 26 LANDSDOWNE STREET, 2139 CAMBRIDGE
Website:: https://beamtx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Beam Therapeutics is a biotechnology company pioneering the development of precision genetic medicines through its proprietary base editing technology. Launched in 2018, the company utilizes a next-generation CRISPR platform designed to make precise, single-letter edits to the genome without creating double-stranded breaks in the DNA. Beam's mission is to provide lifelong cures for patients with serious diseases, focusing on genetic disorders, hematological conditions, and oncology. The company is building a fully integrated platform with a diverse suite of delivery technologies, including viral, nonviral, and electroporation modalities, to advance its portfolio of investigational therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
	2025-11-04 13:11	Quarterly Report 10-Q - Beam Therapeutics Inc. (0001745999) (Filer)	English	1.9 MB
	2025-11-04 13:06	Regulatory News Service 8-K - Beam Therapeutics Inc. (0001745999) (Filer)	English	163.6 KB

Automate Your Workflow. Get a real-time feed of all Beam Therapeutics Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Beam Therapeutics Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Beam Therapeutics Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Moogene Medi Co., Ltd. Develops LNP drug delivery systems for severe diseases, offering R&D to GMP manufacturing support.	South Korea	322970
MORISHITA JINTAN CO.,LTD. Manufactures health products and provides OEM/ODM services using advanced encapsulation technology.	Japan	4524
MUROMACHI CHEMICALS INC. A diversified manufacturer of pharmaceuticals, chemical systems, health foods & functional materials.	Japan	4885
MUSTANG BIO, INC. Developing CAR T-cell and gene therapies for cancers and rare genetic disorders.	United States of America	MBIO
MYUNGMOON PHARM CO.,LTD Develops, manufactures, and commercializes prescription & OTC medicines for global markets.	South Korea	017180
Nanexa AB Develops long-acting injectables using its proprietary nanotechnology for its own pipeline and partners.	Sweden	NANEXA
Nanobiotix Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.	France	NANO
Nanobiotix S.A. Developing a nanotherapeutic radioenhancer that amplifies radiation to destroy solid tumors.	United States of America	NBTX
Nanoform Finland OYJ Pharma tech firm engineering nanoparticles to enhance drug performance and development.	Finland	NANOFH
NanoGroup S.A. Develops patented nanotechnology for oncology and transplantology diagnostics and therapies.	Poland	NNG